Westcove Partners Facilitates Strategic Partnership for Clinical Research of West Florida and Fengate

On October 16, 2026, Westcove Partners, LLC, a highly specialized investment bank, publicly announced its role as the exclusive financial advisor for Clinical Research of West Florida (CRWF) in forging a partnership with Fengate Private Equity. Although the financial specifics of the deal remain undisclosed, the collaboration is expected to enhance CRWF's capabilities in the clinical research landscape significantly.

About Clinical Research of West Florida

Founded in 1995, CRWF has built a robust reputation as a leading independent clinical research organization. With three state-of-the-art facilities strategically located across the Tampa Bay area, the organization has successfully conducted more than a thousand clinical trials spanning various therapeutic areas. Notably, they possess specialized knowledge in complex autoimmune and rheumatology indications. This extensive experience, coupled with a proprietary patient database and established relationships with pathfinding sponsors and Contract Research Organizations (CROs), has made CRWF a trusted player in high-quality trial execution and patient enrollment.

Aydin Keskiner, the Owner and President of CRWF, stated, "Westcove was unquestionably the right partner for us. Their understanding of our business and the clinical research industry was evident throughout the engagement. We always felt supported and confident in their commitment to help us achieve the best possible outcome. Their recognition of the value of our organization has been essential in forming this significant partnership with Fengate."

The Role of Fengate Private Equity

Fengate Private Equity, part of Fengate Asset Management, is a recognized leader in the realm of alternative investments. With over $20 billion in assets under management and a focus on private equity, infrastructure, and real estate, Fengate is well poised to provide the necessary resources and strategic insight to further CRWF's growth ambitions. The collaboration aims to expand CRWF's operational model into new markets and therapeutic areas, leveraging Fengate's expertise in driving sustainable growth.

Bill Bolding, Director at Westcove, emphasized the core attributes of CRWF's operations, stating, "Aydin and his team have a clear vision for expanding their model into new markets. Fengate’s alignment with that vision presents a tremendous opportunity for CRWF to evolve in its next chapter."

The Future of CRWF

As they move forward in this new alliance, both parties are optimistic. Aydin Keskiner elucidated the excitement surrounding this partnership: "We view this as a pivotal moment for our organization. Our collaboration with Fengate will not only enhance our capacity to conduct clinical trials but also expand our reach to more patients in need of novel therapies. We are eager to embark on this journey that promises to bring innovation in clinical research."

CRWF is set to elevate its standing as a clinical research authority through this groundbreaking partnership, which is a testament to the firm’s unwavering commitment to quality and excellence in healthcare. Both Westcove and Fengate are enthusiastic about the positive impact this relationship will have on advancing clinical research capabilities, ultimately benefiting patients and the healthcare industry as a whole.

Conclusion

The strategic partnership between Clinical Research of West Florida and Fengate Private Equity represents a significant milestone in the clinical research arena. As both organizations align their strengths and expertise, they are poised to set new standards in the clinical research landscape, ensuring innovative treatments reach the patients who need them the most. Westcove Partners, with its profound understanding of the healthcare sector, continues to illustrate its value in forging partnerships that drive meaningful progress in the industry.